This is a report on 60 consecutive @entity1 with @entity1860 ( @entity1860 ) who received an allogeneic bone marrow transplant (BMT) in this Unit. Donors were HLA-identical siblings (SIB) (n = 36) or unrelated donors (MUD) (n = 24) matched by serology for @entity2149 and by molecular biology for HLA DR. All @entity1 were prepared with @entity786 120 mg/kg and fractionated total body irradiation 10-12 Gy. GVHD prophylaxis consisted of @entity205 (CsA) starting on day -7 and short-course methotrexate. Bone marrow was unmanipulated in all cases. @entity2803 prophylaxis consisted of @entity1033 for SIBs and foscarnet for @entity46139 . When compared to SIB transplants, MUD @entity1 were younger (29 vs 36 years; P = 0.002), had younger donors (31 vs 39; P = 0.001), had a longer interval between diagnosis and BMT (1459 vs 263 days; P < 0.001) and received a smaller number of nucleated cells at transplant (3.3 vs 4.4 x 10(8)/kg; P = 0.003). More @entity46139 had advanced disease (50 vs 17%, P = 0.005). The median day to 0.5 x 10(9)/l neutrophils was similar in both groups (18 days for SIBs vs 17 days for @entity46139 ; P = 0.06); the median platelet count on days +30, +50, +100 was significantly (P < 0.01) higher in SIB than in MUD @entity1 (122 vs 38, 113 vs 50 and 97 vs 45 x 10(9)/l, respectively). Acute GVHD was scored as absent-mild, moderate, or severe, in 36, 58 and 6% of SIBs vs 25, 42 and 33% in MUD @entity1 (P = 0.01). @entity102 was comparable (P = 0.1). The actuarial risk of CMV antigenemia at 1 year was 60% in both groups. There were six @entity204 in SIB @entity1 (two @entity1778 , two @entity281 , one GVHD, one @entity55 ) and four @entity204 in MUD @entity1 (three acute GVHD and one @entity281 ). Fifty @entity1 survive with a median follow-up of 656 days for SIBs and 485 for @entity46139 . The actuarial 3-year transplant-related mortality is 12% in SIBs and 17% in @entity46139 (P = 0.5); the actuarial relapse is 18% in SIBs vs 6% in @entity46139 (P = 0.4) and 3-year survival 78% in SIBs vs 82% in @entity46139 (P = 0.7). This study suggests that survival of @entity1860 @entity1 after marrow transplantation from unrelated or sibling donors is currently similar, provided the former are well matched. The increased incidence of GVHD in MUD @entity1 is possibly compensated by a lower risk of relapse.

Bone marrow transplantation for XXXX ( @entity1860 ) from unrelated and sibling donors: single center experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2803 :: ('MESH:D003586', 'Disease') :: ['Cytomegalovirus'] @entity1033 :: ('MESH:D000212', 'Chemical') :: ['acyclovir'] @entity46139 :: ('MESH:C531728', 'Disease') :: ['MUDs'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic GVHD'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections'] @entity2149 :: ('3105;3106', 'Gene') :: ['HLA A and B'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']
@entity1860 :: (MESH:D015464,Disease) :: ['chronic myeloid leukemia']
